Insider Transactions in Q1 2024 at Collegium Pharmaceutical, Inc (COLL)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 29
2024
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
995
-1.54%
|
$35,820
$36.76 P/Share
|
|
Feb 26
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-3.37%
|
$360,000
$36.77 P/Share
|
|
Feb 12
2024
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,199
-2.39%
|
$105,567
$33.7 P/Share
|
|
Feb 12
2024
|
Thomas B Smith EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,423
+19.62%
|
-
|
|
Feb 12
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,690
-8.66%
|
$979,770
$33.7 P/Share
|
|
Feb 12
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,286
+17.31%
|
-
|
|
Feb 12
2024
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,321
-7.72%
|
$868,593
$33.7 P/Share
|
|
Feb 12
2024
|
Colleen Tupper EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,456
+18.3%
|
-
|
|
Feb 12
2024
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
128,867
-11.87%
|
$4,252,611
$33.7 P/Share
|
|
Feb 12
2024
|
Joseph Ciaffoni President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
298,734
+23.53%
|
-
|
|
Feb 12
2024
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
31,756
-8.42%
|
$1,047,948
$33.7 P/Share
|
|
Feb 12
2024
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
76,647
+17.76%
|
-
|
|
Jan 16
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
23,560
-17.47%
|
$753,920
$32.28 P/Share
|